Prophylactic Vaccine Development
Infectious Disease
ServiceActive
Key Facts
About ImmuneSpec
Founded in 2017 and based in Leuven, Belgium, ImmuneSpec is a specialized service provider in the immunopeptidomics space. The company leverages a proprietary, high-sensitivity platform to identify peptides presented by MHC molecules, offering crucial insights for biotherapeutic developers in immunogenicity testing, vaccine design, and cancer immunotherapy target validation. As a private, likely pre-revenue or early-revenue company, ImmuneSpec operates on a B2B service model, partnering with pharmaceutical and biotech clients to de-risk and accelerate their R&D pipelines through precise, data-driven epitope mapping.
View full company profileTherapeutic Areas
Other Infectious Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaccine Platform | Biolingus | Research |
| Pipeline Antibiotics | BioQ Pharma | Unknown |
| Antivirals Platform | Qubit Pharmaceuticals | Discovery |
| Antibiotic Development Program | AF ChemPharm | Pre-clinical |
| Optimized VHH vs. SARS-CoV-2 | Ordaos Bio | Pre-clinical |
| AmorphOX Vaccine | Orexo | Preclinical |
| Undisclosed Vaccine Program(s) | Brazos Biomedical | Pre-clinical |
| Undisclosed Asset 1 | Uvax Bio | Research |
| Undisclosed Asset 2 | Uvax Bio | Research |
| Undisclosed Asset 3 | Uvax Bio | Research |
| Vaccine Immune Response (SARS-CoV-2) | CellChorus | Preclinical |
| POCKIT™ Central COVID-19 Assay | GeneReach Biotechnology | commercial |